Till Brian G, Martins Renato G
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N., D3-190, Seattle, Washington 98109, USA.
Head Neck. 2008 Jun;30(6):810-4. doi: 10.1002/hed.20731.
Paclitaxel is not considered to be an active drug in adenoid cystic carcinoma (ACC) of the salivary glands. We report 2 consecutive cases of patients with ACC who responded to paclitaxel.
The patients were: (1) a 58-year-old man with recurrent ACC who developed pulmonary metastases, had progressive disease after a good response to first-line chemotherapy, and then achieved a partial response to weekly single- agent paclitaxel; and (2) a 46-year-old woman with extensive thoracic ACC metastases who achieved a significant response after 2 cycles of paclitaxel chemotherapy.
The first patient died of progressive disease approximately 4 months after completing paclitaxel therapy, and the second patient had disease control after 6 cycles of paclitaxel.
Systemic weekly paclitaxel produced a significant response in 2 patients with ACC of the head and neck, and its use in this disease merits further study.
紫杉醇在涎腺腺样囊性癌（ACC）中不被认为是一种活性药物。我们报告了2例连续的ACC患者对紫杉醇有反应。
患者为：（1）一名58岁男性，复发性ACC伴肺转移，对一线化疗有良好反应后疾病进展，随后对每周单药紫杉醇治疗达到部分缓解；（2）一名46岁女性，广泛的胸部ACC转移，在2周期紫杉醇化疗后取得显著反应。
首例患者在完成紫杉醇治疗后约4个月死于疾病进展，第二例患者在6周期紫杉醇治疗后病情得到控制。
每周一次的全身紫杉醇治疗使2例头颈部ACC患者产生了显著反应，其在该疾病中的应用值得进一步研究。
